Drug Name |
Deferasirox |
Drug ID |
BADD_D00594 |
Description |
Deferasirox is an iron chelator and the first oral medication FDA approved for chronic iron overload in patients receiving long term blood transfusions. |
Indications and Usage |
For the treatment of chronic iron overload due to blood transfusions (transfusional hemosiderosis) in patients 2 years of age and older. |
Marketing Status |
Prescription |
ATC Code |
V03AC03 |
DrugBank ID |
DB01609
|
KEGG ID |
D03669
|
MeSH ID |
D000077588
|
PubChem ID |
214348
|
TTD Drug ID |
D0Q5UQ
|
NDC Product Code |
62332-412; 43598-856; 57664-769; 62332-411; 62756-569; 0078-0469; 70771-1411; 66039-871; 69097-550; 70771-1471; 72647-371; 62512-0078; 68462-494; 69539-021; 31722-012; 69097-391; 57664-770; 58032-2017; 69539-200; 63278-1070; 72647-372; 46708-324; 69452-159; 62332-410; 53104-7713; 72606-014; 11722-040; 69097-570; 43598-851; 62332-324; 67877-549; 69539-022; 66022-0301; 0591-3853; 45963-456; 14501-0049; 46708-410; 62332-325; 46708-879; 72606-013; 62756-570; 69238-1486; 43598-854; 65085-0063; 62332-326; 69238-1704; 70710-1011; 59285-010; 46708-326; 70710-1012; 59651-419; 16714-995; 69539-199; 72205-076; 65727-037; 74436-0323; 57664-768; 68462-495; 46708-325; 69452-160; 0078-0713; 65015-738; 16714-993; 69097-393; 69097-560; 0078-0470; 31722-013; 69539-074; 43598-853; 70700-269; 70771-1409; 49706-2103; 70710-1277; 43598-855; 0078-0468; 65372-1164; 16714-994; 43598-852; 45963-455; 46708-412; 0078-0727; 70771-1472; 72647-373; 68462-496; 67877-553; 69238-1703; 45963-454; 69452-161; 0078-0654; 62756-568; 70771-1473; 69539-023; 67877-550; 0078-0720; 70710-1275; 31722-011; 72606-015; 70771-1410; 69539-075; 67877-551; 70710-1013; 67877-554; 72205-075; 0078-0656; 70700-270; 69238-1702; 0078-0655; 46708-411; 69097-392; 69539-073; 69238-1487; 67877-552; 70700-271; 70710-1276; 69238-1488 |
Synonyms |
Deferasirox | 4-(3,5-Bis-(2-hydroxyphenyl)-(1,2,4)-triazol-1-yl)benzoic acid | ICL 670A | ICL-670A | ICL670A | ICL-670 | ICL670 | ICL 670 | Exjade |